Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched BOTOX® Cosmetic for treating masseter muscle prominence (MMP) in adults in China. This marks the first neurotoxin approved for MMP in China, the largest global market for this treatment. The approval is based on a robust safety profile and clinical trials demonstrating effectiveness in reducing masseter muscle prominence.
Key highlights:
- BOTOX® Cosmetic showed a 5.2mm greater average reduction in facial width compared to placebo
- Results typically lasted 6-9 months
- Improvements were seen in psychosocial impact, attractiveness, and confidence
- Treatment-emergent adverse events were mild to moderate
- 87.3% of study subjects identified as Asian
Allergan Aesthetics plans to expand BOTOX® Cosmetic use for MMP in additional global markets.
AbbVie (NYSE: ABBV) announced new data from its antibody-drug conjugate (ADC) platform to be presented at the European Society for Medical Oncology (ESMO) Congress 2024. Key highlights include:
1. PICCOLO trial: Mirvetuximab soravtansine showed a 51.9% objective response rate in platinum-sensitive ovarian cancer patients.
2. LUMINOSITY trial: Patient-reported outcomes for telisotuzumab vedotin (Teliso-V) in non-small cell lung cancer (NSCLC) patients.
3. Phase 1 study: ABBV-400 showed promising results in pre-treated NSCLC and gastroesophageal cancer patients.
AbbVie plans to submit Teliso-V for accelerated approval in Q3 2024 for previously treated c-Met overexpressing, EGFR wild-type non-squamous NSCLC.
AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.55 per share. The dividend will be payable on November 15, 2024, to stockholders of record as of October 15, 2024. Since its inception in 2013, AbbVie has increased its dividend by more than 285 percent. The company is a member of the S&P Dividend Aristocrats Index, which includes companies that have consistently increased their dividends for at least 25 consecutive years.
NImmune Biopharma has announced a research collaboration with BioTherapeutics, Inc. to advance precision medicines for inflammation and immunology. This partnership will provide NImmune access to BioTherapeutics' preclinical services, regulatory capabilities, and proprietary animal models of disease. The collaboration complements NImmune's existing partnership with NIMML Institute, creating a unique scientific ecosystem for drug development.
This ecosystem has already demonstrated success with the development of NX-13 and its acquisition by AbbVie, Inc. (NYSE: ABBV). The collaboration aims to accelerate the development of NImmune's immunoregulatory drug pipeline, leveraging BioTherapeutics' computational modeling and NIMML Institute's TITAN-X A.I.-powered precision medicine platform.
AbbVie (NYSE: ABBV) has announced the 2024-2025 recipients of its Immunology Scholarship, supporting 45 U.S. students living with chronic immune-mediated diseases. The scholarship, established in 2016, has benefited over 400 undergraduate and graduate students to date. Recipients are equally split among dermatology, gastroenterology, and rheumatology therapeutic areas.
The initiative aims to address the lower graduation rates among young adults with childhood-onset chronic illnesses by providing financial support and empowerment. Applicants are selected based on academic excellence, community leadership, essay submissions, and recommendation letters. The scholarship is open to students pursuing associate, bachelor's, master's, or doctorate degrees who are living with immune-mediated conditions.
SkinMedica®, a brand under Allergan Aesthetics (an AbbVie company, NYSE: ABBV), has launched its new HA5® Hydra Collagen Replenish + Restore Hydrator. This innovative product, designed for all skin types, features:
- Double the amount of hyaluronic acid compared to the original formula
- Hydra Collagen and Advanced VITISENSCE® Technology
- Up to 48 hours of hydration
- Support for the skin's natural moisture retention
The product can be complemented with an in-office DiamondGlow® facial using SkinMedica® HA5® Hydra Collagen Pro-Infusion Serum. Clinical studies show this combination results in skin appearing three times more radiant, hydrated, and visibly plumper after one use.
AbbVie (NYSE: ABBV) announced that the European Commission has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. TEPKINLY is now the first and only subcutaneous T-cell engaging bispecific antibody approved to treat both R/R FL and R/R diffuse large B-cell lymphoma (DLBCL) in the European Union, European Economic Area countries, and Northern Ireland.
The approval is based on data from the Phase 1/2 EPCORE® NHL-1 clinical trial, which showed an overall response rate of 83% and a complete response rate of 63% in R/R FL patients treated with TEPKINLY. The median duration of response was 21.4 months. The safety profile was consistent with previous reports, with cytokine release syndrome being the most common adverse reaction.
AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.
The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the return of JUVÉDERM® Day on August 21, 2024. This second annual event offers exclusive deals and savings through the Allē loyalty program. Highlights include:
1. BOGO Gift Cards: Members can purchase a $75 JUVÉDERM® gift card and receive an additional $75 card free.
2. Allē Flash: Schedule a consultation for a chance to save up to $500 on JUVÉDERM® treatment.
3. Sweepstakes: Get treated by September 30 for a chance to win $10,000.
JUVÉDERM® remains the top chosen hyaluronic acid dermal filler collection globally. The event aims to surpass last year's record-breaking treatment numbers and drive consumers to practices. Allē, serving over 7 million members across ~30,000 practices, offers rewards on various aesthetic treatments and flexible payment plans.
AbbVie (NYSE: ABBV) announced that the European Commission has approved SKYRIZI® (risankizumab) for treating adult patients with moderately to severely active ulcerative colitis (UC). This marks SKYRIZI's fourth approved indication in the European Union. The approval is based on data from two Phase 3 trials: INSPIRE (induction) and COMMAND (maintenance).
Key findings include:
- In INSPIRE, 20% of patients achieved clinical remission at week 12 with SKYRIZI vs 6% with placebo
- In COMMAND, 40% and 38% of patients achieved clinical remission at week 52 with SKYRIZI 180mg and 360mg, respectively, vs 25% in the control group
- Significant improvements in mucosal healing were observed, especially in patients without previous biologic or JAK inhibitor failure
The safety profile was consistent with previous trials, with no new safety risks identified.
